We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms. I Agree
 Information  X 
Enter a valid email address
Show me how to log in   Forgot password?

Company Name matching 'Immunic, Inc.'

Date
Time Source
Company
Announcement
 
02 Aug 2022 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
06 Jul 2022 11:30 am EQS   Immunic, Inc. Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
28 Jun 2022 11:30 am EQS   Immunic, Inc. Immunic to Participate in Industry and Scientific Conferences in July
15 Jun 2022 11:30 am EQS   Immunic, Inc. Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N
08 Jun 2022 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
02 Jun 2022 11:30 am EQS   Immunic, Inc. Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
05 May 2022 11:30 am EQS   Immunic, Inc. Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
25 Apr 2022 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences
16 Mar 2022 10:30 am EQS   Immunic, Inc. Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer
08 Mar 2022 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor and Scientific Conferences in March
18 Feb 2022 11:30 am EQS   Immunic, Inc. Immunic to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of ECCO and Announces Blinded Baseline Characteristics of Phase 2 Trial of Vidofludimus Calcium in Ulcerative Colitis
08 Feb 2022 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor and Scientific Conferences in February
02 Feb 2022 9:01 pm EQS   Immunic, Inc. Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
14 Dec 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
09 Dec 2021 9:01 pm EQS   Immunic, Inc. Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer
23 Nov 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference
18 Nov 2021 9:01 pm EQS   Immunic, Inc. Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis
01 Nov 2021 10:30 am EQS   Immunic, Inc. Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update
28 Oct 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis
27 Oct 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935
14 Oct 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
30 Sep 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
28 Sep 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Scientific and Investor Conferences in October
22 Sep 2021 11:30 am EQS   Immunic, Inc. Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
08 Sep 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor and Scientific Conferences in September
03 Aug 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor Conferences in August
12 Jul 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
01 Jul 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
28 Jun 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
10 Jun 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Industry and Investor Conferences in June
01 Jun 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
15 Apr 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
13 Apr 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
31 Mar 2021 1:50 pm EQS   Immunic, Inc. Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838
02 Mar 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Industry and Investor Conferences in March
18 Feb 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
17 Feb 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
11 Feb 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25
05 Jan 2021 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor Conferences in January
24 Nov 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor Conferences in December
17 Nov 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board
10 Nov 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor and Scientific Conferences in November
02 Nov 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed
20 Oct 2020 11:30 am EQS   Immunic, Inc. EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
29 Sep 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Scientific Conferences in October
28 Sep 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
11 Sep 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
08 Sep 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Scientific and Investor Conferences in September
20 Aug 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
02 Aug 2020 8:00 pm EQS   Immunic, Inc. Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
30 Jul 2020 9:15 pm EQS   Immunic, Inc. Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
29 Jul 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor Conferences in August
27 Jul 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19
22 Jun 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Join Russell 3000(R) Index
15 Jun 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
09 Jun 2020 12:00 pm EQS   Immunic, Inc. Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
29 May 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Participate in Investor and Industry Conferences in June
19 May 2020 11:30 am EQS   Immunic, Inc. Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020
13 May 2020 9:01 pm EQS   Immunic, Inc. Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
21 Apr 2020 9:01 pm EQS   Immunic, Inc. Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients
 


Company Announcements Archive »


a d v e r t i s e m e n t